Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Sacubitril-Valsartan

Diala Nicolas  1 , Preeti Patel, Mirembe Reed
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Sacubitril-Valsartan

Diala Nicolas et al.
Free Books & Documents

Excerpt

Sacubitril-valsartan is the first agent approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) in NYHA class II, III, or IV. Sacubitril-valsartan is used instead of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) and in conjunction with other standard heart-failure treatments (beta-blocker or aldosterone antagonist). Patients must be able to tolerate ACEi or ARB before starting sacubitril or valsartan. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring of sacubitril or valsartan so clinicians can appropriately treat patients with heart failure and related cardiovascular conditions.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Diala Nicolas declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Mirembe Reed declares no relevant financial relationships with ineligible companies.

References

    1. Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, Vader J. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019 Mar;24(2):167-176. - PMC - PubMed
    1. Eadie AL, Brunt KR, Herder M. Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan). Pharmacol Res Perspect. 2021 May;9(3):e00794. - PMC - PubMed
    1. Vicent L, Esteban-Fernández A, Gómez-Bueno M, De-Juan J, Díez-Villanueva P, Iniesta ÁM, Ayesta A, González-Saldívar H, Rojas-González A, Bover-Freire R, Iglesias D, García-Aguado M, Perea-Egido JA, Martínez-Sellés M. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry. J Cardiovasc Pharmacol. 2019 Feb;73(2):118-124. - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW, ACC/AHA Joint Committee Members 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. - PubMed
    1. Shaddy R, Burch M, Kantor PF, Solar-Yohay S, Garito T, Zhang S, Kocun M, Bonnet D. Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial. Circ Heart Fail. 2023 Mar;16(3):e009816. - PMC - PubMed

Publication types

LinkOut - more resources